Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Proc...
June 28 2017 - 4:05AM
A distinguished panel of U.S. dermatologists and plastic surgeons
explored current literature to establish the value of hypochlorous
acid (HOCl) as both a pre- and post-procedure regime aimed at
prevention of infection, reduction of inflammation and management
of scarring, with the objective of enabling optimal outcomes.
The panel of doctors, which included Michael H. Gold, MD, FAAD;
Anneke Andriessen PhD; Steven H. Dayan, MD; Sabrina G. Fabi MD; Z.
Paul Lorenc MD, FACS; and Meagan-Helen Henderson Berg, reviewed
summarized results on the topic while taking into account their own
current clinical practices. A nominal group process for
consensus was used, followed by online reviews of the manuscript,
the consensus subsequently published in the June 2017 edition of
the Journal of Cosmetic Dermatology. The abstract of this
report can be found at:
https://www.ncbi.nlm.nih.gov/pubmed/28370943
The role of hypochlorous acid-containing spray and translucent
scar gel, which combines modified silicone oil with hypochlorous
acid, such as Sonoma Pharmaceutical’s patented Microcyn®
Technology-based products (NASDAQ: SNOA, warrants SNOAW), was
explored as a pre- and post-procedure treatment as well as for scar
management. Based on panel discussions, consensus was reached
regarding clinical recommendations for post-procedure treatment and
scar management.
“Our esteemed panel evaluated multiple clinical studies as well
as their own current clinical protocols,” said Dr. Michael H. Gold,
founder of the Gold Skin Care Center in Nashville, Tennessee and
the Tennessee Clinical Research Center as well as member of the
Vanderbilt University School of Nursing. “We scoured the
internet for credible clinical studies and scientific articles so
as to impartially assess the benefits of hypochlorous acid,
relative to current protocols as they relate to pre- and
post-procedure treatments and scar management. I am excited
about the potential of HOCl to efficaciously and safely treat
wounds and scars. Beyond this, our panel would like to see
larger studies of HOCl against the currently used regimes so as to
further validate our consensus.”
This consensus concluded that hypochlorous acid has been shown
to be an efficacious and safe therapy in pre- and post-procedure
management, hypertrophic and keloid scar prevention and treatment.
Through its potent broad-spectrum antimicrobial activity and
anti-biofilm effects, HOCl solution has been associated with a
lower risk of wound infection than other available treatments
including Hibiclens, betadine and povidone-iodine. It increases
oxygenation at wound sites, which may improve healing time. The
safety of HOCl solution has demonstrated to be comparable to that
of standard local antiseptics. The scar gel formulation of HOCl has
demonstrated efficacy in improving the appearance of hypertrophic
and keloid scars and in relieving associated pruritus and pain. The
HOCl scar gel also appears to be safe and well tolerated.
More information regarding Sonoma Pharmaceuticals’ portfolio of
hypochlorous acid-based dermatology products including Alevicyn™
Dermal Spray, Alevicyn™ Antipruritic Gel, Subuderm™ Topical Gel and
Celacyn™ Scar Management Gel is available at www.intraderm.com.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K. The
Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals®, IntraDerm Pharmaceutials®, Sebuderm™,
Alevicyn™, Celacyn™ and Microcyn® Technology are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@Sonomais.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Apr 2023 to Apr 2024